cyrilzakka/clinical-trials huggingface dataset:
The Effect of Zinc on Iron Bioavailability From Fortified Extruded Rice Fortified With Ferric Pyrophosphate

Investigation of Iron Bioavailability from extruded rice grains fortified with Ferric Pyrophosphate alone or in combination with different Zinc Compounds; Ferrous Sulfate serves as a Reference.

Ferric Pyrophosphate (FePP) is a water-insoluble, food grade, iron compound widely used to fortify rice and other foods as it causes no organoleptic changes to the food vehicles. However, it is only of low absorption in man and its absorption can be influenced by a variety of compounds. The effect of co-fortification of rice with ZnO respectively ZnSO4 on iron bioavailability in extruded rice fortified with FePP has never been investigated.

Eligibility Criteria:
Inclusion Criteria:

* Female
* Serum Ferritin Level \< 15 µg/L
* Body weight \<65 kg
* Signed informed consent 4. Body Mass Index in the range of 18.5 to 25

Exclusion Criteria:

-
A Study of Multiple Doses of LY3305677 in Healthy Participants

The purposes of this study are to determine:

* The safety of LY3305677 and any side effects that might be associated with it.
* How much LY3305677 gets into the bloodstream and how long it takes the body to remove it in healthy participants, including those of Japanese origin.
* The effect LY3305677 has on the body, particularly the effect on blood glucose levels.

This study will last approximately 17 weeks not including screening. Screening is required within 4 weeks prior to start of the study.

This study is for research purposes only and is not intended to treat any medical conditions.


Eligibility Criteria:
Inclusion Criteria:

* Are overtly healthy males or females, as determined by medical history and physical examination
* Women not of child-bearing potential due to surgical sterilization confirmed by medical history or menopause
* Are first-generation Japanese or non-Japanese. First-generation Japanese is defined as the participant, the participant's biological parents, and all of the participant's grandparents are of exclusive Japanese descent and have been born in Japan
* Have a body weight of more than 54 kilograms (kg)

Exclusion Criteria:

* Currently enrolled in a clinical study or have participated in a study within the past 3 months
* Have an abnormality in the 12-lead electrocardiogram (ECG) at screening
* Have history of pancreatitis
* Have known or ongoing psychiatric disorders
* Have undergone bariatric surgery or have used any drugs for weight loss
* Have a history of alcoholism
* Currently smoke more than 10 cigarettes a day
Vibrotactile Feedback During Vestibular Therapy

This study evaluates the use of vibrotactile feedback to traditional vestibular treatment protocols. Half the patients will have vibrotactile feedback added to their treatment protocols while the other half will undergo traditional vestibular treatment without vibrotactile feedback.

Vestibular and balance rehabilitation is an effective way to improve balance for individuals with balance impairments by using the strategies of adaptation, habituation, or substitution. Typical vestibular treatment is usually 3 sessions per week for 6 weeks. For people with uncompensated unilateral vestibular hypofunction or bilateral vestibular loss, recovery/adaptation is often incomplete and chronic balance impairments result.

Vibrotactile feedback (VTF) is a strategy of substitution, or augmentation, to replace disrupted or absent vestibular function. The sensory information replaces disrupted or absent vestibular function to give persons additional signals about their body position in space. Real-time VTF applied to the trunk has been shown to decrease postural sway but the long-term benefits of training with VTF on balance and function have not been examined.

Eligibility Criteria:
Inclusion Criteria:

* unilateral peripheral vestibular hypofunction
* bilateral peripheral vestibular hypofunction

Exclusion Criteria:

* confounding neurologic or neuromuscular disorders
* pregnancy
* inability to stand for 3 minutes
* recent lower extremity fracture/severe sprain within the last 6 months
* previous lower extremity joint replacement
* incapacitating back or lower extremity pain
* body too large for equipment
Evaluate the Efficacy and Safety of Pasireotide LAR (Long Acting Release) on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma.

This study assessed pasireotide LAR efficacy on patients with non-functioning pituitary adenomas concerning tumor growth.


Eligibility Criteria:
Inclusion Criteria:

* Non-functioning pituitary adenoma ≥ 1cm, patients without any previous treatment for the tumor
* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

Exclusion Criteria:

* Patients who required a surgical intervention for relief of any sign or symptom associated with tumor compression
* Previous pituitary surgery
* Previous medical treatment for pituitary tumor
* Patients who had received pituitary irradiation within 10 years prior to randomization
* Prolactin (PRL) levels \> 100 ng/mL. PRL evaluation should have been performed with diluted samples to ensure "hook effect." was avoided
* Patients who presented prolactinomas, acromegaly or Cushing's disease
* Patients with compression of the optic chiasm causing acute clinically significant visual field defects
An Observational Study Evaluating SYMLIN® (Pramlintide Acetate) Injection Use in Insulin Using Patients With Type 2 and Type 1 Diabetes

This is an open label, observational study designed to collect data that characterize the use of SYMLIN following the introduction of the medication into the marketplace. Health care providers and subjects selected for study participation are intended to be representative of those providers prescribing, and subjects receiving, SYMLIN therapy.


Eligibility Criteria:
Inclusion Criteria:

* The following inclusion criteria are consistent with information in the SYMLIN package insert and apply to insulin using patients with type 2 or type 1 diabetes who:

  * Have failed to achieve the desired or optimal level of glycemic control despite utilizing appropriate, individualized insulin regimens
  * Have A1C \<=9.0% within 3 months of study enrollment
  * Are receiving ongoing diabetes care under the guidance of a Health Care Provider (HCP) trained in the use of SYMLIN

Exclusion Criteria:

* The following exclusion criteria are consistent with the SYMLIN package insert and specifically exclude patients who:

  * Are poorly compliant with their current insulin regimen, as defined by their HCP
  * Are poorly compliant with prescribed blood glucose self monitoring, as defined by their HCP
  * Have experienced recurrent patient-ascertained severe hypoglycemia requiring assistance during the past 6 months
  * Have hypoglycemia unawareness
  * Have a confirmed diagnosis of gastroparesis
  * Require the use of drugs that stimulate gastrointestinal motility
  * Are female and pregnant or lactating and for whom the HCP determines the potential benefit does not justify the potential risk to the fetus or infant
  * Have been treated with SYMLIN within 3 months prior to study start
Web-based Genetic Research on Parkinson's Disease

The purpose of this study is to examine how genes and environment affect risk for Parkinson's disease.

23andMe has created a web-based Parkinson's research initiative to understand the genetic associations found between Parkinson's patients' DNA and their disease. To learn more, visit: https://www.23andme.com/pd/. You can participate in this research initiative without leaving home. If you are eligible to participate, we will send you an in-home 23andMe DNA kit at no cost. We will ask you short online surveys (15-20) about your Parkinson's journey, symptoms, and response to treatment. Enrollment is on-going and open to individuals who have been diagnosed with Parkinson's disease and are residents of the U.S. Participants receive access to ancestry information and uninterpreted genetic data. Participants will also receive regular updates on our research efforts and findings.

Eligibility Criteria:
Inclusion Criteria:

* diagnosis of Parkinson's disease by a physician

Exclusion Criteria:

* diagnoses other than Parkinson's, including:
* progressive supranuclear palsy (PSP)
* multiple system atrophy (MSA)
* Shy-Drager syndrome
* spinal cerebella ataxia (SCA)
* atypical parkinsonism
* parkinsonism due to medications, drug-induced parkinsonism
* vascular parkinsonism
* frontotemporal dementia with parkinsonism
Investigation of Faldaprevir Effect on Pharmacokinetics of Raltegravir

The primary objective of this trial is to investigate effect of faldaprevir on steady state pharmacokinetics of raltegravir.

The assessment of safety and tolerability will be an additional objective of this trial.


Eligibility Criteria:
Inclusion criteria:

1. healthy male subjects

Exclusion criteria:

1. Any relevant deviation from healthy conditions
Vestibular Stimulation Therapy for Rhythmic Movement Disorder

This study aims to a) investigate the feasibility of the detection of episodes of RMD using contactless 3D video analysis and customised analysis software and b) the use of vestibular stimulation as a therapy for childhood rhythmic movement disorder.

Rhythmic movement disorder (RMD) is a childhood onset sleep disorder that is characterised by repetitive movements that involve large muscle groups, such as body rocking, rolling and head banging. These rhythmic movements are performed prior to and during sleep and as such can disturb sleep with clinical consequences. There is no standard measure to quantify the severity of rhythmic movements. 3D video offers a contactless method of achieving this without disrupting the child's sleep. Vestibular stimulation has a soothing effect and might be effective in promoting sleep. Furthermore, mild vestibular stimulation in the form of gentle rocking movements generated by the Somnomat device might function as a stimulation substitute for the child's RMD with therapeutic potential.

This study aims to a) investigate the feasibility of the detection of episodes of RMD using contactless 3D video analysis and customised analysis software and b) the use of vestibular stimulation as a therapy for childhood rhythmic movement disorder.

Eligibility Criteria:
Inclusion Criteria:

* RMD diagnosis based on ICSD III criteria or RMD suspected
* Typically developing
* Child and accompanying adult are legally allowed to enter Switzerland without a visa
* Both child and parent/legal guardian understand easy English or German

Exclusion Criteria:

* Moderate or severe learning disability
* Neurological disorder (incl. autism, epilepsy, medicinally treated ADHD)
* Currently using medication that influences sleep
* Known diseases of the vestibular system
* Self-reported sensitivity for motion sickness
* Body height \> 1.95 m (due to the constraints of the setup)
* Body weight \> 130 kg (due to the constraints of the setup)
* Flu, cold or other acute disease on study day that might influence measurements
* Pregnancy
Gut Microbiota and Nonpuerperal Mastitis

Nonpuerperal mastitis (NPM), mainly including Plasma cell mastitis (PCM) and Granulomatous mastitis (GM), which clinical presentation is an accessible and painful breast mass accompanied by skin redness and swelling, nipple retraction and fistula formation . Much progress has been made in exploring the etiology and pathogenesis of NPM, while the exact etiology remains unknown, NPM is thought to arise from interactions between genetic susceptibility factors, epigenetic effects, and various environmental factors. While microbiota as an environment factor to some inflammatory and autoimmune diseases accept widespread attention, if gut microbiota also as a risk factor for NPM, it is worthy to be considered.

NPM is common in young women of reproductive age with a history of lactation and childbearing . The main clinical presentation is an accessible and painful breast mass accompanied by skin redness and swelling, nipple retraction and fistula formation

. The imaging of NPM is not specific, with NPM mimicking breast cancer in imaging . NPM etiology is associated with several factors, such as autoimmunity, bacterial infections , estrogen and progesterone imbalance , and hyperprolactinemia . In recent years, NPM has become a common benign breast disease, especially in the Mediterranean region and developing countries in Asia, such as China . Currently, the associations between bacterial infections and NPM are among the important issues attracting research interest. This study tried to reveal the roles of gut microbiota in NPM. Further understanding of the roles of gut microbiota in this disease may lead to the development of methods for personalized therapy.

Eligibility Criteria:
Inclusion Criteria:

* Aged 18 to 65 years
* Patients of NPM

Exclusion Criteria:

* Pregnancy
* Lactation
* Cigarette smoking
* Alcohol addiction
* Hypertension
* Diabetes mellitus
* Lipid dysregulation
* BMI \> 27 \<18.5
* Recent (\< 1 months prior) use of antibiotics, probiotics, prebiotics, synbiotic, hormonal medication, laxatives, proton pump inhibitors, insulin sensitizers or Chinese herbal medicine
* History of disease with an autoimmune component, such as multiple sclerosis(MS), rheumatoid arthritis, irritable bowel disease(IBS), or irritable bowel syndrome(IBD)
* History of malignancy or any gastrointestinal tract surgery
Ultrasound Detection and Characterization of Subclinical Hypertrophy in Diabetes

This is a pilot study to enroll 100 people to assess the incidence of lipohypertrophy as detected with ultrasound and its impact on glycemic variability.

Lipohypertrophy is a well documented phenomenon in patients with diabetes in which hypertrophy and differentiation of adipocytes occurs in the dermal reticular layer at the sites of subcutaneous insulin injection. Currently, lipohypertrophy is assessed by palpating insulin injection sites. The detection on early, non palpable (subclinical) lipohypertrophy remains difficult in the clinical setting. Recent studies have identified distinct ultrasonographic features of hyperechogenicity in areas of adipose tissue consistent with clinical evidence of lipohypertrophy at insulin injection sites, and have detected changes int he thickness of subcutaneous tissue where not clinically evident in population of patients with type 1 diabetes. Lipohypertrophy can adversely affect glycemic control. Injecting into lipohypertrophic areas leads to poor absorption and the need for increasing doses of insulin.

In this study study participants will undergo an assessment for lipohypertrophy during a scheduled visit at the VGH Diabetes Centre. A Diabetes Nurse will assess lipohypertrophy by palpation according to the FIT Protocol. A second diabetes nurse who was not present at the palpation will assess insulin injection sites for lipohypertrophy by ultrasound using a linear probe.

Eligibility Criteria:
Inclusion Criteria:

* 19 years of age or older
* Type 1 or Type 2 diabetes
* Using insulin to manage diabetes for at least 2 years

Exclusion Criteria:

* Using insulin pumps, insulin secretagogues, Glucagon-Like Peptide-1 (GLP-1) agonists to manage diabetes
* Use of immunosuppressant agents
* Women who are pregnant
Concurrent Nab-P/Carboplatin and Thoracic Radiotherapy in Squamous Cell Lung Cancer

Nab-paclitaxel and carboplatin showed better treatment response compared with cremophor-based paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer, especially for squamous cell cancer. This study is conducted to evaluate the efficacy and safety of nab-paclitaxel, carboplatin and concurrent radiotherapy in patients with local advanced inoperable squamous cell lung cancer.

This study was conducted to explore the efficacy and safety of concurrent concurrent nab-paclitaxel, carboplatin and thoracic radiotherapy in inoperable local advanced squamous cell lung cancer. Patients will be given nab-paclitaxel weekly at a dose of 40mg/m2, in combination with carboplatin (AUC 2) weekly during concurrent chemoradiotherapy. Thoracic radiation was administered at a dose of 60-66 Gy/30-33 fractions, both 3 dimensional conformal and intensity modulated radiation therapy are allowed.

Eligibility Criteria:
Inclusion Criteria:

* Age: 18 Years to 70 Years
* Performance status of 0 to 1 on the Eastern Cooperative Oncology Group (ECOG) Scale.
* Previously untreated, histological documented, inoperable stage III squamous cell carcinoma of lung, excluding those with pericardial, pleural effusion, and those with contralateral hilar or contralateral supraclavicular lymph nodes.
* Patients must have measurable disease according to RECIST criteria, and all detectable tumor can be encompassed by radiation therapy fields.
* Patient must have adequate blood, liver, lungs and kidney function within the requirements of this study.
* Female patients of child-bearing potential must test negative for pregnancy at the time of enrollment based on a serum pregnancy test. Male and female patients must agree to use a reliable method of birth control during and for 3 months following the last dose of study drug.
* Patients must sign a study-specific informed consent form prior to study entry.

Exclusion Criteria:

* Complete tumor resection, recurrent disease, or those patients eligible for definitive surgery.
* Previous chemotherapy or previous biologic response modifiers for current lung cancer.
* Patient has previously had thoracic radiation therapy.
* Prior or concurrent malignancy except non-melanomatous skin cancer unless disease-free for five years or more.
* Serious concomitant disorders that would compromise the safety of the patient, or compromise the patient's ability to complete the study, at the discretion of the investigator.
* History of significant neurological or mental disorder, including seizures or dementia.
The Multi-Center Study of Shear Wave Elastography on Thyroid Nodules

The incidence rates of thyroid cancers have increased in the past decade. Additionally, up to 68% of people have thyroid nodules. Consequently, a precise evaluation of thyroid nodules is very important and can avoid unnecessary biopsy of benign nodules. Shear wave elastography(SWE), a novel ultrasound-based elastographic method, is a new real-time, quantitative, operator-independent, and reproducible technique. Briefly, shear wave elastography uses a radiation force produced by an ultrasonic beam to stress tissues and ultrafast sonographic tracking techniques to measure the speed of shear waves. Based on the Young modulus formula, tissue elasticity can be derived from the shear wave propagation speed, and a real-time color-coded elastogram can be displayed, showing softer tissue in blue and stiffer tissue in red.

There are lots of research confirmed that SWE has a certain value in the diagnosis of thyroid carcinoma. These studies include prospective studies and retrospective studies, but both belong to a single center study. It has not been applied to the study of the multicenter of thyroid disease.

The main purpose of the study is to assess the performance of SWE for identification of benign and malignant thyroid nodules and calculate the optimal cutoff value for each parameter in multicenter study; the secondary purpose is to evaluate the application value of SWE for uncertain nodules by FNA.

SWE can prove the diagnostic performance in the differentiation of benign and malignant thyroid lesions

1. Main purpose

   1. to assess the performance of SWE for identification of benign and malignant thyroid nodules in multicenter study;
   2. calculate the optimal cutoff value for each parameter in multicenter study
2. Secondary purpose to evaluate the application value of SWE for uncertain nodules by FNA.

Eligibility Criteria:
Inclusion Criteria

1. the size of the lesion is between 0.5～4cm
2. the solid components in the lesion\>50%；
3. all patients perform FNA or surgery in one month after SWE examination

Exclusion Criteria:

1. patients who are unwilling or unable to provide informed consent
2. Woman who is pregnant or breastfeeding;
3. Thyroid nodules with calcified which is beyond 1/2 diameter of lesion
4. patients who have history of surgery、FNA or thermal ablation in ipsilateral thyroid
5. patients who have serious cardiopulmonary diseases
Training Based On Declarative Memory Cues Improved Gait In Patients With Parkinson's Disease

Deficits in automatic motor control, characteristic of Parkinson's disease (PD), contribute to progressive impairment in gait performance. The use of declarative memory cues in order to promote the engagement of attention and activation of the next movement in gait may minimize the consequences of lack of automatic control. The purpose of this study is to verify the long-term efficiency of a new strategy based on declarative memory cue to improve the gait performance and independence in daily life activities (DLA) in patients with PD.

Background: Deficits in automatic motor control, characteristic of Parkinson's disease (PD), contribute to progressive impairment in gait performance. The use of declarative memory cues in order to promote the engagement of attention and activation of the next movement in gait may minimize the consequences of lack of automatic control.

Objectives: To verify the long-term efficiency of a new strategy based on declarative memory cue to improve the gait performance and independence in daily life activities (DLA) in patients with PD.

Design: Parallel prospective, single blind, randomized clinical trial. Setting: Brazilian Parkinson Association. Participants: Forty-four patients with PD in stages 2-3 of disease evolution according to Hoehn and Yahr Classification Interventions: The experimental training (ET) consisted of eight gait training sessions, twice a week, using the declarative memory cues strategy (DMCS). The control training (CT) consisted of a similar gait training without DMCS.

Primary outcome measure: Gait performance in terms of speed and stride length. Secondary outcome measure: Independence in DLA according to Section II of the Unified Parkinson's Disease Rating Scale.

Randomization: Participants were randomized into a control group (CG), which performed the CT, and an experimental group (EG), which performed the ET, through blinded drawing of names.

Statistical analysis: The gait performance and ADL independence before, 2 and 60 days after the end of training were compared for CG and EG using Repeated-measures analysis of variance (RM-ANOVA).

Eligibility Criteria:
Inclusion Criteria:

* diagnosis of idiopathic Parkinson's disease according to the UK Brain Bank criteria;
* in stage 2-3 of the disease evolution according to the Hoehn and Yahr;
* treated with levodopa or its synergists;
* capable to ambulate independently indoors without aid;
* referring 5 to 15 years of education;
* good visual and auditory acuity.

Exclusion Criteria:

* presence of other neurological (excluding PD), orthopedic or cardiopulmonary problems;
* visual and auditory deficiency;
* dementia \[assessed by the Mini Mental State Examination (MMSE), cut-off 23\];
* depression \[according to the Geriatric Depression Scale (GDS-15), cut-off 6\]
* participation in other physical therapy training.
Telephone Interview of Patients That Participated in the the Pivotal Betaferon MS Trial.

The purpose of this study is to investigate the clinical status of patients who participated in the original pivotal Betaseron study at 20 years after randomized treatment initiationStudy end-points include:

1. Mortality - All-cause mortality - Cause specific mortality - Multiple sclerosis-related mortality
2. EDSS (Expanded Disability Status Scale)
3. Cognition
4. Resource use
5. SPMS (Secondary Progressive Multiple Sclerosis) status
6. Employment history


Eligibility Criteria:
Inclusion Criteria:

* Previously enrolled in the Betaseron pivotal study protocols TB01-35686 in the US and TB01-35886 in Canada (total, N=372)
* Patient, caregiver, or legal guardian must provide written informed consent
* Patient must confirm her/his ability and agreement to participate in the study at the beginning of the phone call